Moomoo AIのまとめ
NeuroSense Therapeutics, a clinical-stage biotechnology company, reported a net loss of $10.1 million for the year ended December 31, 2023, compared to a net loss of $10.5 million for the previous year. The company's research and development expenses increased by 30.2% to $7.3 million, primarily due to clinical study costs and an increase in employee numbers. General and administrative expenses slightly decreased by 3.9% to $4.8 million. Financing income netted a gain of $1.9 million, mainly from the revaluation of warrants. As of December 31, 2023, NeuroSense had cash and cash equivalents of $2.6 million. The company's financial statements have been prepared on a going concern basis, and it has been indicated that existing cash will not suffice for the next 12 months without additional financing. NeuroSense's lead product candidate, PrimeC, is in development for treating neurodegenerative diseases such as ALS, with ongoing clinical trials and regulatory processes. The company has not generated any revenue to date and expects to continue incurring losses as it invests in product development and seeks regulatory approvals.
NeuroSense Therapeutics, a clinical-stage biotechnology company, reported a net loss of $10.1 million for the year ended December 31, 2023, compared to a net loss of $10.5 million for the previous year. The company's research and development expenses increased by 30.2% to $7.3 million, primarily due to clinical study costs and an increase in employee numbers. General and administrative expenses slightly decreased by 3.9% to $4.8 million. Financing income netted a gain of $1.9 million, mainly from the revaluation of warrants. As of December 31, 2023, NeuroSense had cash and cash equivalents of $2.6 million. The company's financial statements have been prepared on a going concern basis, and it has been indicated that existing cash will not suffice for the next 12 months without additional financing. NeuroSense's lead product candidate, PrimeC, is in development for treating neurodegenerative diseases such as ALS, with ongoing clinical trials and regulatory processes. The company has not generated any revenue to date and expects to continue incurring losses as it invests in product development and seeks regulatory approvals.
臨床段階のバイオテクノロジー企業であるNeuroSense Therapeuticsは、2023年12月31日までの1年間の純損失が$10.1 百万で、前年の純損失$10.5百万に比べ減少しました。同社の研究開発費用は30.2％増の$7.3百万で、主に臨床試験費用と従業員数の増加によるものです。一方、一般管理費用は3.9％減の$4.8百万にわずかに減少しました。また、warrantsの再評価により、財務収益は$1.9百万の利益を計上しました。2023年12月31日時点で、NeuroSenseは現金及び現金同等物を$2.6百万保有しています。同社の財務諸表は事業継続の前提で作成され、追加の資金調...すべて展開
臨床段階のバイオテクノロジー企業であるNeuroSense Therapeuticsは、2023年12月31日までの1年間の純損失が$10.1 百万で、前年の純損失$10.5百万に比べ減少しました。同社の研究開発費用は30.2％増の$7.3百万で、主に臨床試験費用と従業員数の増加によるものです。一方、一般管理費用は3.9％減の$4.8百万にわずかに減少しました。また、warrantsの再評価により、財務収益は$1.9百万の利益を計上しました。2023年12月31日時点で、NeuroSenseは現金及び現金同等物を$2.6百万保有しています。同社の財務諸表は事業継続の前提で作成され、追加の資金調達なしには次の12か月間を維持するのに十分な現金があるとは示されていません。NeuroSenseの主力製品候補であるPrimeCは、ALSなどの神経変性疾患の治療において開発中であり、臨床試験や規制プロセスが継続中です。同社はこれまでに何ら収益を上げておらず、製品開発への投資や規制承認の取得に投資しつづけ、損失を計上することが予想されています。
役に立った
役に立たない
この開示の添付ファイルは以下です：